ASCENDIS PHARMA A/S: Financial statements 2019
CVR: 29918791
Source: annual report 2019, Danish Business Authority
01/01/2019 – 31/12/2019
ASCENDIS PHARMA A/S (CVR 29918791) has filed annual accounts for 2019. In 2019, the company reported revenue of EUR 13,375,000 and a net result of EUR -218,016,000 compared with EUR -130,097,000 the year before. That is an increase of 26.4% compared with the year before. The profit margin was -1,630%. Equity in the 2019 report amounted to EUR 597,114,000. The solvency ratio was 88.2%.
- Revenue
- EUR 13,375,000
- Profit/Loss
- EUR -218,016,000
- Equity
- EUR 597,114,000
- Total Assets
- EUR 676,732,000
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2019 | 13.4 mio. EUR | - | -218 mio. EUR | 597.1 mio. EUR | - |
| 2018 | 10.6 mio. EUR | - | -130.1 mio. EUR | 280.1 mio. EUR | - |
| 2017 | 1.5 mio. EUR | - | -123.9 mio. EUR | 187.2 mio. EUR | - |
| 2016 | 4.6 mio. EUR | - | -68.5 mio. EUR | 176.6 mio. EUR | - |
| 2015 | 8.1 mio. EUR | - | -32.9 mio. EUR | 120.3 mio. EUR | - |
Official annual report
Screen every Danish company
Combine filters on financials, industry, geography, property and risk, and instantly see which companies match.
Try company screeningEvents in 2019
ASCENDIS PHARMA A/S has published its annual report for 2018. Revenue came to DKK 10,581,000, and the net result was DKK -130,097,000.
About ASCENDIS PHARMA A/S
ASCENDIS PHARMA A/S is a Danish company of the type Aktieselskab based in Hellerup, founded in 2006. The company is registered under the industry Fremstilling af farmaceutiske præparater. The company was previously named ASCENDIS PHARMA ApS and CADENZA PARTNERS ApS. The management consists of Jan Møller Mikkelsen, Anni Lotte Kirstine Pedersen and Michael Wolff Jensen. The board consists of Albert Cha (chair), Jan Møller Mikkelsen, Jean-Jacques Bienaime and Lars Holtug. The company is owned by Cede & Co. The company has 688 employees (2026). In 2025, the company reported revenue of EUR 720,132,000 and a net result of EUR -228,034,000 compared with EUR -378,084,000 the year before. Equity in the 2025 report amounted to EUR -162,821,000.